Related Experiment Video
Updated: Jul 3, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Antibody-Drug Conjugates in Triple Negative Breast Cancer
Merve Keskinkilic1, Ruth Sacks2
1Department of Medical Oncology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
Abstract:
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.
Insights
Triple negative breast cancer (TNBC) is aggressive, necessitating novel treatments. Antibody-drug conjugates (ADCs) show promise, with ongoing trials exploring their efficacy in TNBC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple negative breast cancer (TNBC) represents 15-20% of all breast cancer cases.
- TNBC is characterized by its heterogeneity and poor prognosis, highlighting the need for advanced therapeutic strategies.
- Conventional chemotherapy offers limited options for TNBC, particularly in early-stage and palliative care settings.
Purpose of the Study:
- To review completed and ongoing clinical trials of antibody-drug conjugates (ADCs) in the treatment of triple negative breast cancer.
- To assess the potential of ADCs as a novel therapeutic approach for TNBC.
Main Methods:
- Literature review of clinical trials focusing on ADCs in TNBC.
- Analysis of data from completed and ongoing studies involving specific ADCs like sacituzumab govitecan and trastuzumab deruxtecan.
Main Results:
- ADCs have demonstrated impressive results in the metastatic TNBC setting.
- Ongoing trials are evaluating the efficacy and safety of various ADCs in different stages of TNBC.
Conclusions:
- Antibody-drug conjugates represent a promising new class of therapeutics for triple negative breast cancer.
- Further research and clinical trials are crucial to establish the role of ADCs in improving outcomes for TNBC patients.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
